首页 | 本学科首页   官方微博 | 高级检索  
检索        

成人接种重组酵母乙型肝炎疫苗免疫效果观察
作者姓名:Shi J  Wang X  Wang G  Xu Z  Yang Z  Zheng L  Li Z  Guo N  Wu X  Liang Z
作者单位:1. 110001,沈阳,中国医科大学第一临床医院临床流行病教研室
2. 辽宁省北票市中小学卫生保健所体检科
3. 辽宁省北票市第二人民医院
4. 卫生部生物药物制品检定所疫苗二室
基金项目:国家“九五”攻关课题 (96 90 6 0 3 0 3 )
摘    要:目的:探讨重组酵母乙型肝炎(乙肝)疫苗(YDV)对厉人的免疫效果及其安全性,方法:在辽宁省北票市部分学校随机选择一般健康状况良好、乙肝表面抗原(HBsAg)、乙肝表面抗体(抗-HBs)及乙肝核心抗体(抗-HBc)三项指标均为阴性且体温正常的22-58岁的教师124名,按0、1、6个月程序,每次5μg/0.5ml接种国产重组酵母乙肝疫苗。结果:免疫后3、7、12和24个月时,抗-HBs阳转率分别为35.0%,83.3%,65.5%和32.7%,抗抗-HBs平均滴度分别为12.6、402.0、70.3和20.3mIU/ml;抗-HBs阳转率及其滴度均在7个月时达到高峰,以后又急剧下降,免疫后各月女性抗-HBs阳转率和滴度均高于男性;<35岁组的抗体阳性率高于≥35岁组,但12个月时,二比较差异有显意义;免疫3d后未出现局部和全身不良反应。结论:重组酵母乙肝疫苗对成人具有良好的免疫原性和安全性,其抗-HBs持续时间有待进一步观察。

关 键 词:成人  接种  重组酵母乙型肝炎疫苗  免疫效果观察
修稿时间:2001年11月20

Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in adults
Shi J,Wang X,Wang G,Xu Z,Yang Z,Zheng L,Li Z,Guo N,Wu X,Liang Z.Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in adults[J].Chinese Journal of Preventive Medicine,2002,36(6):366-369.
Authors:Shi Jingpu  Wang Xin  Wang Guihua  Xu Zhanmin  Yang Zhiqi  Zheng Liguo  Li Zhengyuan  Guo Naiquan  Wu Xiaoyin  Liang Zhenglun
Institution:First Clinical College, China Medical University, Shenyang 110001, China.
Abstract:OBJECTIVE: To study the immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine (YDV) in adults. METHODS: One hundred and twenty-four healthy teachers aged 22 approximately 58 years with serum negative HBsAg, anti-HBs, anti-HBc and with normal temperature were randomly selected from Beipiao city, Liaoning province. All the subjects were immunized with 5 microg/0.5 ml of YDV made by Beijing Institute of Biologic Products, for three doses at an interval of one and six months, respectively. RESULTS: The positivity of serum anti-HBs was 35.0%, 83.3%, 65.5% and 32.7% with a geometric mean titre (GMT) of 12.6 mIU/ml, 402.0 mIU/ml, 70.3 mIU/ml and 20.3 mIU/ml, respectively, three, seven, 12 and 24 months after immunization. The positivity and GMT of serum anti-HBs appeared the highest seven months after immunization, then began to decrease sharply. The positivity and GMT of serum anti-HBs in women was higher than that in men either three, or seven, or 12, or 24 months after immunization. The positivity of serum anti-HBs in those of 35 years or over was lower than that less than 35 years, seven months after immunization, but no age difference could be found 12 months after immunization. No local or systematic adverse reactions were found in all the subjects within three days after immunization. CONCLUSION: The recombinant yeast-derived hepatitis B vaccine (YDV) is immunogenic and safe for adults, but the persistency of serum anti-HBs in after immunization should be followed-up further.
Keywords:Vaccines  synthetic  Hepatitis B vaccines  Vaccination  Immunity
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号